{"id":4192,"date":"2023-07-25T20:33:35","date_gmt":"2023-07-26T01:33:35","guid":{"rendered":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/?p=4192"},"modified":"2023-07-25T20:36:50","modified_gmt":"2023-07-26T01:36:50","slug":"gsks-arexvy-to-lead-new-rsv-vaccines-sales-race-with-moderna-a-close-second-report","status":"publish","type":"post","link":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/2023\/07\/25\/gsks-arexvy-to-lead-new-rsv-vaccines-sales-race-with-moderna-a-close-second-report\/","title":{"rendered":"GSK\u2019s Arexvy to lead new RSV vaccines sales race with Moderna a close second: report"},"content":{"rendered":"<div class=\"panel body-content\"><div class=\"panel__container\">\n<p><a href=\"https:\/\/www.fiercepharma.com\/marketing\/gsks-arexvy-lead-new-rsv-vaccines-sales-race-moderna-close-second-report\">Fierce Pharma<\/a> <\/p>\n\n\n\n<p>We waited years for working RSV vaccines and in 2023, in the space of just a few weeks, we had two come all at once, with another on the horizon and a fresh approval for an RSV prevention med.<\/p>\n\n\n\n<p>But how will the RSV market shake out? Well, the analysts at GlobalData crunched the numbers and forecast that GSK\u2019s Arexvy will be the market leader.<\/p>\n\n\n\n<p>Analysts at the firm see the total RSV market hitting $9 billion by 2029, up from the $1 billion expected this year, and Arexvy is projected to \u201cclimb steadily and emerge as a market leader,\u201d the firm said in its latest report.<\/p>\n\n\n\n<p>Over this seven-year forecast, GlobalData reckons GSK\u2019s shot will generate more than a quarter of that total global RSV market, with just over $2.5 billion in sales by 2029.&nbsp;<\/p>\n\n\n\n<p>Arexvy was the first-ever RSV vaccine to gain an approval, getting a yes from the FDA back in May and swiftly followed with an EU green light, something that will help boost its overall sales trajectory.<\/p>\n\n\n\n<p>Pfizer\u2019s rival RSV vaccine Abrysvo, which is yet to nab European approval, got its FDA approval mere weeks after GSK, but is set to make just $1.7 billion over the same period.<\/p>\n\n\n\n<p>That would put in an unexpected third place, behind an RSV vaccine that isn\u2019t even approved yet: namely, Moderna\u2019s mRNA-1345.<\/p>\n<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Fierce Pharma We waited years for working RSV vaccines and in 2023, in the space of just a few weeks, we had two come all at once, with another on the horizon and a fresh approval for an RSV prevention med. But how will the RSV market shake out? Well, the analysts at GlobalData crunched [&hellip;]<\/p>\n","protected":false},"author":11,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[43,8],"tags":[],"class_list":["post-4192","post","type-post","status-publish","format-standard","hentry","category-rsv","category-vaccine-headlines"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts\/4192","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/comments?post=4192"}],"version-history":[{"count":1,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts\/4192\/revisions"}],"predecessor-version":[{"id":4193,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts\/4192\/revisions\/4193"}],"wp:attachment":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/media?parent=4192"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/categories?post=4192"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/tags?post=4192"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}